Nanjing Leads Biolabs (HKG:9887) dosed the first patient in a phase 2 trial of LBL-034 following strong phase I data, a Monday filing with the Hong Kong bourse said.
The study aims to evaluate the efficacy and safety of the drug in patients with various relapsed/refractory plasma cell neoplasms, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.